Aktuellt
SENASTE
As we expected, the Q1 report itself bore no surprises but served to highlight FluoGuide’s progress in de-risking and diversifying its R&D programme. The Q1 result was better than we expected, owing mainly to a more rapid closure of activities from the ph1/2 clinical trial, as well as grant income. The key near-term milestones are the high-grade glioma efficacy readout and phase 2a lung cancer trial, both by YE 2022, through which FluoGuide is financed.
LÄS MER
